Clinical and experimental rheumatology最新文献_第5页

Research trends of the aetiology of systemic lupus erythematosus in the past 10 years: a bibliometric analysis (2014-2023). 近10年系统性红斑狼疮病因学研究趋势：文献计量学分析（2014-2023）

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-05-01 DOI: 10.55563/clinexprheumatol/yvqg5k

Yong-Long Yan, Ya-Shuang Su, Jing-Jing Cao, Jie Lin, Jun-Lie Sun, Cui-Fang Zhang, Rui-De Su

{"title":"Research trends of the aetiology of systemic lupus erythematosus in the past 10 years: a bibliometric analysis (2014-2023).","authors":"Yong-Long Yan, Ya-Shuang Su, Jing-Jing Cao, Jie Lin, Jun-Lie Sun, Cui-Fang Zhang, Rui-De Su","doi":"10.55563/clinexprheumatol/yvqg5k","DOIUrl":"10.55563/clinexprheumatol/yvqg5k","url":null,"abstract":"Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by a complex aetiology that encompasses genetic, environmental, and immunological factors. A comprehensive understanding of SLE aetiology is essential for the development of effective therapeutic strategies and the enhancement of patient outcomes. This study aims to provide a thorough bibliometric analysis of research concerning the aetiology of SLE conducted over the past decade.Methods: A bibliometric analysis was conducted based on articles published between January 2014 and December 2023, retrieved from the Web of Science Core Collection database. The analysis employed the R package 'bibliometrix', as well as VOSviewer and CiteSpace.Results: A total of 5,825 publications were analysed. The results underscore the global collaborative nature of SLE research, with significant contributions from China, the USA, and Japan. Notable institutions included Harvard University, the Chinese Academy of Medical Sciences, and the Egyptian Knowledge Bank. Influential journals in the field comprised Arthritis & Rheumatology, Annals of the Rheumatic Diseases, and Frontiers in Immunology. Key word analysis revealed a recent emphasis on terms such as 'management','efficacy', and 'safety', together with emerging interests in 'health' and 'genes'.Conclusions: This study provides a bibliometric analysis of SLE aetiology research, highlighting evolving research trends, influential studies, and collaborative networks. The findings indicate a shift in research focus from specific disease pathogenesis and expression toward genetic mechanisms, diagnostic approaches, and clinical applications. Future research on SLE aetiology is likely to prioritise investigations into DNA, genes, and validating existing findings.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1650-1660"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel nomogram based on the identification of sTREM2 as a biomarker to predict developing neuropsychiatric systemic lupus erythematosus in lupus patients. 一种基于sTREM2作为生物标志物的新形态图预测狼疮患者发生神经精神系统性红斑狼疮。

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-05-14 DOI: 10.55563/clinexprheumatol/1tcgmj

Xiujiao Wang, Jian Tang, Fengyun Lu, Xue Zhang, Juan Yao, Ping Gu, Mei Sun, Yanyan Wang

{"title":"A novel nomogram based on the identification of sTREM2 as a biomarker to predict developing neuropsychiatric systemic lupus erythematosus in lupus patients.","authors":"Xiujiao Wang, Jian Tang, Fengyun Lu, Xue Zhang, Juan Yao, Ping Gu, Mei Sun, Yanyan Wang","doi":"10.55563/clinexprheumatol/1tcgmj","DOIUrl":"10.55563/clinexprheumatol/1tcgmj","url":null,"abstract":"Objectives: This study aimed to identify potential biomarkers and construct a nomogram able to predict the development of neuropsychiatric systemic lupus erythematosus (NPSLE) among SLE patients.Methods: Using bioinformatics analysis, TREM2 was identified as an upregulated gene in NPSLE, participating in various pathological pathways of NPSLE. This study included 80 NPSLE patients and three matched SLE controls with no neuropsychiatric events (non-NPSLE controls) for each of the NPSLE patients. Both serum and cerebrospinal fluid (CSF) concentrations of soluble TREM2 (sTREM2) were assessed. The diagnostic capability of sTREM2 for NPSLE was evaluated using the receiver-operating characteristic curve (ROC curves). The study subsequently integrated a substantial volume of clinical data. Following missing data imputation, patients were randomly allocated to either the training set or the validation set. The Boruta algorithm and Multiple analyses were utilized for constructing the nomogram. Diagnostic performance was assessed using ROC curves, the Hosmer-Lemeshow test, and clinical decision curves.Results: sTREM2 levels were notably elevated in both serum and CSF of NPSLE patients compared to non-NPSLE controls. Serum TREM2 concentrations correlated with NPSLE severity and neuropsychiatric state. Notably, higher SLE Disease Activity Index (SLEDAI), increased systemic lupus international collaborating clinics (SLICC)/ACR damage index (SDI), prolonged activated partial thromboplastin time (APTT), a higher serum B cells, and elevated serum sTREM2 levels emerged as significant predictors for NPSLE.Conclusions: sTREM2 presents as a promising biomarker for NPSLE diagnosis. The nomogram that includes serum sTREM2 level as one of the predictors is effective for distinguishing NPSLE from non-NPSLE patients.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1582-1592"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic performance of particle-based multi-analyte technology compared to indirect immunofluorescence in screening for anti-nuclear antibodies in patients with autoimmune rheumatic diseases. 颗粒基多分析物技术与间接免疫荧光在自身免疫性风湿病患者抗核抗体筛查中的诊断性能比较

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-05-08 DOI: 10.55563/clinexprheumatol/h03g16

Francesca Buzzulini, Danilo Villalta, Giulia Previtali, Maria Grazia Alessio, Giacomo Cafaro, Elena Bartoloni, Roberto Gerli, Nicola Bizzaro

{"title":"Diagnostic performance of particle-based multi-analyte technology compared to indirect immunofluorescence in screening for anti-nuclear antibodies in patients with autoimmune rheumatic diseases.","authors":"Francesca Buzzulini, Danilo Villalta, Giulia Previtali, Maria Grazia Alessio, Giacomo Cafaro, Elena Bartoloni, Roberto Gerli, Nicola Bizzaro","doi":"10.55563/clinexprheumatol/h03g16","DOIUrl":"10.55563/clinexprheumatol/h03g16","url":null,"abstract":"Objectives: In autoimmune rheumatic disease (ARD), ANA testing is crucial for orienting clinical diagnosis and further diagnostic workups. We evaluated the performance of a fully automated system using particle-based multi-analyte technology (PMAT) and compared it to indirect immunofluorescence (IIF) on HEp-2 cells.Methods: Serum samples from 1241 subjects were collected in 13 Italian rheumatology centres. The ARD group (782 samples) included 164 patients affected by systemic lupus erythematosus, 277 by Sjögren's syndrome, 132 by systemic sclerosis, 106 by idiopathic inflammatory myopathy, and 103 by undifferentiated connective tissue disease. The control group comprised 120 healthy donors, 221 patients affected by other autoimmune/inflammatory disorders, and 118 patients affected by acute or chronic infections.Results: In the overall ARD population, HEp-2 IIF showed higher sensitivity when compared to Aptiva/PMAT (92.8 vs. 82.6%) except in the case of idiopathic inflammatory myopathy (58.5% vs. 82.1%). Conversely, Aptiva/PMAT showed higher specificity (77.9% vs. 54.0%) and a higher likelihood ratio for positive results (3.81 vs. 2.08). Double-positive samples provided an LR for positive results higher than one method alone (6.31).Conclusions: This is the first study comparing Aptiva/PMAT against HEp-2 IIF in ANA detection. While the diagnostic sensitivity of this novel method is lower than that of HEp-2 IIF, its high specificity is a valuable tool in the diagnosis of patients affected by ARD and improves their stratification into specific disease subsets. The combined use of HEp-2 IIF and Aptiva/PMAT assays increases diagnostic accuracy and significantly enhances the potential to accurately classify patients affected by ARDs.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1622-1628"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduction of non-classical monocytes that suppress interferon-α in patients with systemic lupus erythematosus. 系统性红斑狼疮患者抑制干扰素-α的非经典单核细胞减少。

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-04-23 DOI: 10.55563/clinexprheumatol/ziktdx

Akina Ishii, Shingo Nakayamada, Naoaki Ohkubo, Yusuke Miyazaki, Shigeru Iwata, Junpei Annan, Naohiro Hashimoto, Kei Sakata, Yoshiya Tanaka

{"title":"Reduction of non-classical monocytes that suppress interferon-α in patients with systemic lupus erythematosus.","authors":"Akina Ishii, Shingo Nakayamada, Naoaki Ohkubo, Yusuke Miyazaki, Shigeru Iwata, Junpei Annan, Naohiro Hashimoto, Kei Sakata, Yoshiya Tanaka","doi":"10.55563/clinexprheumatol/ziktdx","DOIUrl":"10.55563/clinexprheumatol/ziktdx","url":null,"abstract":"Objectives: Monocytes are known to be involved in both adaptive and innate immune responses, though their roles in the pathogenesis of systemic lupus erythematosus (SLE) are still unclear. Here, we performed phenotypic and functional analyses of each monocyte subset.Methods: Peripheral blood from patients with autoimmune diseases (SLE: n=53, rheumatoid arthritis: n=12, systemic sclerosis: n=36) was analysed using flow cytometry to compare the number of each monocyte subset and the expression levels of the cell surface markers of patients to those of healthy donors (n=28).Results: The number of CD14dimCD16+ non-classical monocytes in peripheral blood from SLE patients was significantly decreased compared with those from healthy donors and patients with other autoimmune diseases. The number of circulating non-classical monocytes was inversely correlated to SLE disease activity. The number of non-classical monocytes was not related to the use of glucocorticoids or to the presence or absence of specific tissue inflammation. The expression levels of cell surface molecules and the survival rate of non-classical monocytes of patients with SLE were similar to those of healthy donors. An in vitro functional assay revealed that non-classical monocytes suppressed IFN-α production from PBMCs or plasmacytoid DCs, and cell-cell contact through ICAM-4 seemed to be important in this process.Conclusions: Our study demonstrated that the number of circulating non-classical monocytes, which has been shown to have the ability to suppress IFN-α production, was decreased in SLE patients, and this might be related to the excess IFN signature in SLE patients.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1568-1576"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents. 生物制剂治疗类风湿关节炎患者输注/注射相关反应的特征

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-04-18 DOI: 10.55563/clinexprheumatol/z9894l

Ji-Won Kim, Sun-Kyung Lee, Kichul Shin, Ju-Yang Jung, Chang-Hee Suh, Jinhyun Kim, Hyoun-Ah Kim

{"title":"Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents.","authors":"Ji-Won Kim, Sun-Kyung Lee, Kichul Shin, Ju-Yang Jung, Chang-Hee Suh, Jinhyun Kim, Hyoun-Ah Kim","doi":"10.55563/clinexprheumatol/z9894l","DOIUrl":"10.55563/clinexprheumatol/z9894l","url":null,"abstract":"Objectives: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have transformed the management of rheumatoid arthritis (RA), but their efficacy can be limited by infusion/injection-related reactions (IRRs). This study investigated demographic and clinical factors associated with IRRs in patients with RA using data from the Korean College of Rheumatology Biologics & Targeted Therapy (KOBIO) Registry.Methods: We analysed 1,832 patients with RA, categorising them into IRR and non-IRR groups. Demographic, disease characteristics, and treatment histories were compared. A Sankey plot visualised bDMARD switching patterns, and multivariable logistic regression identified IRR-independent predictors.Results: IRRs occurred in 9.7% of patients and were significantly associated with younger age (mean 49.9 vs. 54.9 years; OR=1.793, p=0.014), secondary Sjögren's syndrome (OR=2.175, p=0.035), and prior leflunomide use (OR=1.497, p=0.015). Abatacept (OR=0.263, p<0.001), tocilizumab (OR=0.419, p<0.001), and golimumab (OR=0.345, p=0.006) were associated with reduced IRR risk compared to infliximab. Following IRRs, use of etanercept, infliximab, and adalimumab declined, while tocilizumab and Janus kinase (JAK) inhibitors increased.Conclusions: IRRs are common among RA patients receiving bDMARDs, particularly in younger individuals or those with prior leflunomide use. Abatacept, tocilizumab, and JAK inhibitors represent safer alternatives, underscoring the need for individualised treatment strategies.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1629-1637"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A panel incorporating genetic variants of RIN3, NLRC3, and SLX4 shows promise in predicting remission after tofacitinib therapy in rheumatoid arthritis patients. 一个包含RIN3、NLRC3和SLX4基因变异的小组显示，在预测类风湿关节炎患者接受托法替尼治疗后的缓解方面有希望。

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-07-21 DOI: 10.55563/clinexprheumatol/lkqekd

Po-Ku Chen, Yi-Ming Chen, Chia-Fong Cho, Jeremy J J W Chen, Jian-Ching Wu, David Daf, Ning-Rong Gong, Der-Yuan Chen

{"title":"A panel incorporating genetic variants of RIN3, NLRC3, and SLX4 shows promise in predicting remission after tofacitinib therapy in rheumatoid arthritis patients.","authors":"Po-Ku Chen, Yi-Ming Chen, Chia-Fong Cho, Jeremy J J W Chen, Jian-Ching Wu, David Daf, Ning-Rong Gong, Der-Yuan Chen","doi":"10.55563/clinexprheumatol/lkqekd","DOIUrl":"10.55563/clinexprheumatol/lkqekd","url":null,"abstract":"Objectives: To promote a treat-to-target goal of tofacitinib therapy, there are unmet needs to predict therapeutic response before treatment. Utilising whole-exome sequencing (WES) and real-time polymerase chain reaction (RT-PCR) analysis, we aim to identify predictors of achieving remission after tofacitinib therapy in rheumatoid arthritis (RA) patients.Methods: We enrolled 242 patients who had received 24-week tofacitinib therapy, including 94 patients (Cohort-1) underwent WES analysis in the discovery stage and 148 patients (Cohort-2) were validated with RT-PCR assays or Sanger sequencing in the replication stage. Disease activity was assessed using the 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR), and therapeutic response at week24 was considered remission if DAS28-ESR <2.6.Results: The WES analysis identified ten variants of RIN3, NLRC3, and SLX4 genes that were predictive of achieving remission after tofacitinib therapy, and its results were completely consistent with those from TaqMan assay or Sanger sequencing. Combined variants of RIN3, NLRC3, and SLX4 genes could predict achieving remission with AUC 0.831, specificity 97.4%, and accuracy 91.5% (Cohort-1). With validation in Cohort-2, a panel incorporating genetic variants of RIN3, NLRC3, and SLX4 showed a high specificity 97.0% and accuracy 86.0%. Using multiplexed one-step RT-PCR assay, this genetic panel still predicts remission with a high specificity 97.0% and accuracy of 88.0%. The significant differences in plasma levels of NLRC3, caspase-1, and IL-6 between the mutant gene and naive gene support the results of the gene ontology analysis.Conclusions: Combined variants of RIN3, NLRC3, and SLX4 genes have great potential for predicting remission in tofacitinib-treated patients.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1548-1553"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and glucocorticoid sparing of dupilumab in IgG4-related disease: a case series and literature review. dupilumab在igg4相关疾病中的疗效和糖皮质激素节约：病例系列和文献综述

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-05-31 DOI: 10.55563/clinexprheumatol/nui493

Flora Finet, Lucile Sesé, Sébastien Abad, Ondine Walter, Chantal Raherison-Semjen, Achille Aouba, Marine Trenec, Alban Deroux, Nicolas Schleinitz, Benjamin Terrier, Robin Dhôte

{"title":"Efficacy and glucocorticoid sparing of dupilumab in IgG4-related disease: a case series and literature review.","authors":"Flora Finet, Lucile Sesé, Sébastien Abad, Ondine Walter, Chantal Raherison-Semjen, Achille Aouba, Marine Trenec, Alban Deroux, Nicolas Schleinitz, Benjamin Terrier, Robin Dhôte","doi":"10.55563/clinexprheumatol/nui493","DOIUrl":"10.55563/clinexprheumatol/nui493","url":null,"abstract":"Objectives: IgG4-related disease (IgG4-RD) is a multisystem fibro-inflammatory disorder for which glucocorticoids (GC) represent the initial therapeutic intervention. Second-line treatments are not currently codified. The use of dupilumab, an inhibitor of interleukin (IL)-4 and IL-13 signalling, has recently been described as a potential alternative treatment. The aim of this study was to describe the characteristics of patients IgG4-RD treated with dupilumab and to evaluate its impact on disease control.Methods: We conducted a French multicentre retrospective study based on standardised questionnaires distributed to physicians via professional networks. The patients included had to meet 2019 ACR/EULAR criteria or the comprehensive diagnostic criteria for IgG4-RD, and to have been treated with dupilumab. Efficacy was assessed using the IgG4-Related Disease Responder Index.Results: A total of seven patients were included in the study. The rationale for initiating dupilumab was based on the presence of severe asthma, nasosinusal polyps and/or atopic dermatitis. A complete response was observed in three patients, while four patients displayed a partial response. In all cases, GC sparing was achieved. A review of the literature revealed nine out of the ten cases reported where a partial or complete reduction of the disorder was documented, along with GC sparing.Conclusions: These preliminary findings need to be confirmed, but may offer arguments in favour of a possible efficacy of dupilumab in the treatment of IgG4-RD.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1661-1666"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stem cell-derived extracellular vesicles: a functional immunomodulator for cell-free therapy of autoimmune diseases. 干细胞来源的细胞外囊泡：一种用于自身免疫性疾病无细胞治疗的功能性免疫调节剂。

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-04-23 DOI: 10.55563/clinexprheumatol/exbsv0

Haoxi Ni, Haoting Zhan, Rongrong Wang, Jingdi Zhang, Ye Guo, Yongzhe Li

{"title":"Stem cell-derived extracellular vesicles: a functional immunomodulator for cell-free therapy of autoimmune diseases.","authors":"Haoxi Ni, Haoting Zhan, Rongrong Wang, Jingdi Zhang, Ye Guo, Yongzhe Li","doi":"10.55563/clinexprheumatol/exbsv0","DOIUrl":"10.55563/clinexprheumatol/exbsv0","url":null,"abstract":"Patients with autoimmune diseases (AIDs) seldom receive efficient clinical management and timely therapy.Although certain immunomodulatory drugs or biologics currently in use have been shown to decelerate AID progression, potential complications and the extended treatment duration affect the prognosis and living quality of patients.Extracellular vesicles (EVs) have attracted significant interest as a cell-free therapeutic approach with reduced side effects. Research has indicated that stem cell-derived EVs (SC-EVs) can modulate the immune response by suppressing hyper-immunity and inflammation. Of note, SC-EVs are anticipated to serve as a potential alternative to traditional cell therapy. The present review explores the effects of different isolation methods on the quality and quantity of EVs derived from various sample sources. It also discusses the mechanisms through which SC-EVs can be used for AID treatment. In addition, the paper summarises the classic preclinical findings of SC-EVs in AID in recent years.Finally, the potential challenges of SC-EVs before receiving approval for clinical application have been elucidated, thereby offering novel insights for future studies on SC-EVs in AIDs.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1678-1690"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ChatGPT's response regarding ankylosing spondylitis-related questions. 关于强直性脊柱炎相关问题的回复。

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-03-13 DOI: 10.55563/clinexprheumatol/ig7k68

Shuang Li, Chunyan Huang, Xiaoqing Chen

引用次数: 0

Application of vascular index based on superb microvascular imaging technique for assessing disease activity in rheumatoid arthritis patients with signal-positive joints. 基于高超微血管成像技术的血管指数在类风湿关节炎信号阳性患者疾病活动性评估中的应用。

IF 3.4 4区医学

Clinical and experimental rheumatology Pub Date : 2025-09-01 Epub Date: 2025-05-01 DOI: 10.55563/clinexprheumatol/8x1nhn

Yan Song, Jingyi Ma, Tianshu Chu, Ming Wu, Xijun Zhang, Haohui Zhu

{"title":"Application of vascular index based on superb microvascular imaging technique for assessing disease activity in rheumatoid arthritis patients with signal-positive joints.","authors":"Yan Song, Jingyi Ma, Tianshu Chu, Ming Wu, Xijun Zhang, Haohui Zhu","doi":"10.55563/clinexprheumatol/8x1nhn","DOIUrl":"10.55563/clinexprheumatol/8x1nhn","url":null,"abstract":"Objectives: To explore the value of the vascular index (VI) based on superb microvascular imaging (SMI) technique in assessing rheumatoid arthritis (RA) disease activity.Methods: The study involved 119 RA patients who underwent SMI examinations of 28 joints. Observers obtained the VI values by manually drawing the area of interest and calculating the sum of the VI values for each patient to obtain the VIsum, and then dividing the VIsum by the number of signal-positive joints to obtain the VIstand. Data of patients' 28-joint Disease Activity Score (DAS28) and laboratory tests were also collected. The relationship between VI parameters and clinical indexes as well as the differences of VI parameters among groups with different disease activity were investigated. Moreover, the cut-off values of VI parameters to identify RA patients with DAS28 <2.6/DAS28 ≤3.2 were calculated using the receiver operating characteristic (ROC) curves.Results: VIsum, VIstand correlated with clinical and laboratory indicators, especially with DAS28 (r=0.740, 0.659, respectively, p<0.05). The differences of VIsum and VIstand among the 4 groups of patients were statistically significant (p<0.05). VIsum had higher diagnostic efficacy than VIstand for identifying patients in remission or in low and below activity. With a VIsum cut-off value of 35.5/47.8, the area under the ROC curve for identifying DAS28 <2.6/DAS28 ≤3.2 was 0.872/0.846.Conclusions: As a quantitative indicator to assess synovitis activity of RA patients, SMI-based VI was helpful in assessing RA disease activity.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1554-1560"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0